Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annu...( ROCKVILLE Md. Oct. 22 /- Vanda Ph...),Health

ROCKVILLE, Md., Oct. 22 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it will present five posters on the pharmacogenetics of iloperidone at the 57th American Society of Human Genetics (ASHG) annual meeting to be held in San Diego, CA, from October 23 through October 27, 2007. This announcement follows the submission of the NDA filing for iloperidone on September 27, 2007. Iloperidone is an investigational atypical antipsychotic for the treatment of schizophrenia.

The following posters will be presented on Thursday, October 25, 2007, from 4:30 p.m. to 6:30 p.m. PDT, at the San Diego Convention Center.

POSTER 1035 - Whole Genome Association Study Identifies Polymorphisms in

the NPAS3 Gene Associated with Enhanced Response to

Iloperidone Treatment in Patients with Schizophrenia

POSTER 1036 - Pharmacogenetic Study of Iloperidone Treatment in Patients

with Schizophrenia Identifies Markers Associated with

Efficacy

POSTER 1037 - Pharmacogenetic Analysis Shows Differences in Markers

Associated with Response Between Two Atypical

Antipsychotics, Iloperidone and Ziprasidone, in the

Treatment of Patients with Schizophrenia

POSTER 1039 - Whole Genome Association Study Identifies Polymorphisms in

the CERKL Gene Associated with QT Prolongation during

Iloperidone Treatment of Patients with Schizophrenia

POSTER 1040 - Single-Nucleotide Polymorphisms in the CYP2D6 Gene Are

Correlated with Iloperidone Drug Exposure Levels, Affecting

'/>"/>